TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29846956

Group type: EXPERIMENTAL
Intervention: Supersized alcopops
Number of subjects: 309

Group type: COMPARATOR
Intervention: Beer
Number of subjects: 309
Study: 26707592

Group type: EXPERIMENTAL
Intervention: Fostamatinib 200 mg BID
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg BID
Number of subjects: 68
Study: 24306002

Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerin (BCG)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerin (BCG) + DMT
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 22196968

Group type: EXPERIMENTAL
Intervention: 1-year treatment: induction: IFN alfa-2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks, maintenance: IFN alfa-2b, 10 MU (flat dose), SC, 3 days/week for 12 months (n = 285)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: 2 years of same treatment as Arm B (n = 285)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Observation only (n = 284)
Number of subjects: 855
Study: 20658921

Group type: EXPERIMENTAL
Intervention: Acapella
Number of subjects: 30

Group type: COMPARATOR
Intervention: Threshold inspiratory muscle trainer
Number of subjects: 30
Study: 16359823

Group type: EXPERIMENTAL
Intervention: Psoriasis patients (PSO)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls (n=25)
Number of subjects: 23
Study: 15316947

Group type: EXPERIMENTAL
Intervention: Haloperidol (neuroleptic known to prolong QTc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-step off-drug QT correction analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-step off- and on-drug QT analysis
Number of subjects: 0
Study: 11139800

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 5000 units subcutaneously every 8 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously daily
Number of subjects: 0
Study: 9265931

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.kg‐1 with bupivacaine 0.175%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with bupivacaine 0.175%
Number of subjects: 40
Study: 8396082

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Comparator agents (co-amoxiclav, amoxycillin, penicillin V, erythromycin, dicloxacillin, flucloxacillin)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Comparator agents
Number of subjects: 1129
Study: 3089691

Group type: EXPERIMENTAL
Intervention: Trimoprostil 1.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Trimoprostil 3.0 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31045455

Group type: EXPERIMENTAL
Intervention: AVF ligation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 29924907

Group type: EXPERIMENTAL
Intervention: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and oral tamoxifen (40 mg/day for 20 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and topical tamoxifen (0.1% tamoxifen citrate for 20 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard meglumine antimoniate (20 mg/kg/day for 20 days)
Number of subjects: 38
Study: 27084921

Group type: EXPERIMENTAL
Intervention: Isavuconazole (20, 40, or 60 mg/kg every 24 h after a 90 mg/kg loading dose for 12 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isavuconazole (clinical dosing regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isavuconazole
Number of subjects: 0
Study: 25420830

Group type: EXPERIMENTAL
Intervention: Liberal fluid strategy (Group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Restrictive fluid therapy (Group B)
Number of subjects: 89
Study: 23186301

Group type: EXPERIMENTAL
Intervention: AGATE intervention (cell-phone-based intervention with SMS text message reminders)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided)
Number of subjects: 105
Study: 20359937

Group type: EXPERIMENTAL
Intervention: Pain biology education and group exercise classes (EDEX)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pain biology education alone (ED)
Number of subjects: 38
Study: 18541792

Group type: EXPERIMENTAL
Intervention: Presence of lesions on baseline non-contrast-enhanced MRI
Number of subjects: 389

Group type: COMPARATOR
Intervention: No lesions on baseline brain MRI
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: 1 or more lesions on baseline brain MRI
Number of subjects: 389

Group type: COMPARATOR
Intervention: Baseline factors (male sex, optic disc swelling, atypical features) in patients without lesions
Number of subjects: 389
Study: 17855096

Group type: EXPERIMENTAL
Intervention: Resistance Strengthening (RS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active Exercise (AE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both RS and AE
Number of subjects: 20
Study: 12914803

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Group cognitive therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 71
Study: 10966892

Group type: EXPERIMENTAL
Intervention: Vitamin A-fortified pandesal (60g containing approximately 133 microg retinol equivalents), consumed 5 days/week for 30 weeks
Number of subjects: 835

Group type: COMPARATOR
Intervention: Nonfortified pandesal, consumed 5 days/week for 30 weeks
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Vitamin A-fortified pandesal
Number of subjects: 835
Study: 9574332

Group type: EXPERIMENTAL
Intervention: Automatic pen for subcutaneous injections of low molecular heparin
Number of subjects: 51
Study: 8365195

Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene and 25,000 IU vitamin A as retinyl palmitate (intervention)
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18000
Study: 3944976

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 219

Group type: COMPARATOR
Intervention: Bismuth subsalicylate
Number of subjects: 219
Study: 29966112

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 26096349

Group type: EXPERIMENTAL
Intervention: Basic and complex skills (Group B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Basic skills (Group A)
Number of subjects: 55
Study: 24973340

Group type: EXPERIMENTAL
Intervention: Reduction mammaplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Follow-up for 6 months
Number of subjects: 60
Study: 23070968

Group type: EXPERIMENTAL
Intervention: Rhinoseptoplasty with inferior turbinate reduction through submucosal diathermy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rhinoseptoplasty without inferior turbinate reduction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rhinoseptoplasty with inferior turbinate reduction
Number of subjects: 50
Study: 20958851

Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 18840077

Group type: EXPERIMENTAL
Intervention: 750 mg single dose of orally administered fluconazole
Number of subjects: 220

Group type: COMPARATOR
Intervention: 150 mg of orally administered fluconazole once per day for 2 weeks
Number of subjects: 220
Study: 16650048

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus and Bifidobacteria lactis)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12828815

Group type: EXPERIMENTAL
Intervention: High causal uncertainty
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low causal uncertainty
Number of subjects: 72
Study: 11379466

Group type: EXPERIMENTAL
Intervention: Griseofulvin 500 mg daily for 10 days
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo and personal hygiene (restricted bathing)
Number of subjects: 225
Study: 8784124

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1729427

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 6390194

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 263
Study: 29514317

Group type: EXPERIMENTAL
Intervention: Nicotine patch (Nicoderm 14 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nicotine spray (Nicotrol, 2 × 1 mg/trial)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo patch plus placebo spray
Number of subjects: 31
Study: 28028730

Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMAb) + erlotinib
Number of subjects: 636

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Onartuzumab exposure
Number of subjects: 636
Study: 25790943

Group type: EXPERIMENTAL
Intervention: 60 mg slow‐release isosorbide‐5-mononitrate (ISMN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23194157

Group type: EXPERIMENTAL
Intervention: Statin-exposed pregnancies
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (non-exposed pregnancies)
Number of subjects: 249
Study: 22355644

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19325186

Group type: EXPERIMENTAL
Intervention: Motivational synchronous music
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oudeterous synchronous music
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-music control
Number of subjects: 30
Study: 16462503

Group type: EXPERIMENTAL
Intervention: 8-session structured multidisciplinary intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard-care arm
Number of subjects: 115
Study: 16279258

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (LVRS) plus medical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 0
Study: 11744593

Group type: EXPERIMENTAL
Intervention: Lightwand intubation (LN group)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Fibreoptic intubation (FN group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Lightwand intubation (LH group)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Fibreoptic intubation (FH group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both techniques (lightwand and fibreoptic)
Number of subjects: 88
Study: 9329348

Group type: EXPERIMENTAL
Intervention: 35 mg hydrocortisone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8440853

Group type: EXPERIMENTAL
Intervention: Various interventions from the FICSIT trials; specific interventions not detailed in the abstract.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on control interventions not available.
Number of subjects: 0
Study: 3525386

Group type: EXPERIMENTAL
Intervention: Oral acyclovir plus 5% acyclovir cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral acyclovir plus matching placebo cream
Number of subjects: 50
Study: 31614330

Group type: EXPERIMENTAL
Intervention: Polarized training (POL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Threshold training (THR)
Number of subjects: 20
Study: 28566441

Group type: EXPERIMENTAL
Intervention: Weekly Jintrolong (0.2 mg/kg/week)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Daily rhGH (0.25 mg/kg/week)
Number of subjects: 451
Study: 25986472

Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Usual Care (RCT control group)
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Matched Nonparticipants (Usual Care)
Number of subjects: 3230
Study: 23474384

Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 177

Group type: COMPARATOR
Intervention: Preference group (varied treatments)
Number of subjects: 177
Study: 21937848

Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation (3 mg/day) for 4 or 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Astaxanthin supplementation (1 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19430742

Group type: EXPERIMENTAL
Intervention: Combination of two antihistamines (levocetirizine 10 mg/fexofenadine 360 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination of three antihistamines (levocetirizine 10 mg/fexofenadine 360 mg/azelastine 4 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High dosage desloratadine (20 mg)
Number of subjects: 67
Study: 16377455

Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 216

Group type: COMPARATOR
Intervention: Parallel treatment
Number of subjects: 216
Study: 15162242

Group type: COMPARATOR
Intervention: Long distance competitive cyclists
Number of subjects: 20
Study: 12027916

Group type: EXPERIMENTAL
Intervention: 100% seizure reduction
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 75-99% seizure reduction
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 50-74% seizure reduction
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 0-50% increase or decrease in seizure frequency
Number of subjects: 134
Study: 9564642

Group type: EXPERIMENTAL
Intervention: GnRH‐a (buserelin acetate, 600 μg/d for six weeks) plus hMG (conventional doses for 14 cycles)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-dose hMG (for 17 cycles)
Number of subjects: 20
Study: 7647025

Group type: EXPERIMENTAL
Intervention: 10 mg oral nicorandil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg oral nicorandil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 2768721

Group type: EXPERIMENTAL
Intervention: Biphasic pulse
Number of subjects: 22

Group type: COMPARATOR
Intervention: Monophasic pulse
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both waveforms
Number of subjects: 22
Study: 782146

Group type: EXPERIMENTAL
Intervention: Low dosage heparin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 110
Study: 31623498

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg/d) following ROCKET AF criteria
Number of subjects: 3162

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg/d) following J-ROCKET AF criteria
Number of subjects: 3162

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg/d) following ROCKET AF criteria
Number of subjects: 3162

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/d) following J-ROCKET AF criteria
Number of subjects: 3162

Group type: COMPARATOR
Intervention: Rivaroxaban (20 mg/d) and (15 mg/d)
Number of subjects: 3162

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3162
Study: 29132740

Group type: EXPERIMENTAL
Intervention: Symbiotics (12 g/day of Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium bifidum, and fructooligosaccharides)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Symbiotics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medium absorption complex carbohydrate
Number of subjects: 60
Study: 26426092

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Overall SELECT population
Number of subjects: 30
Study: 23328338

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (0.1 g tid) for 3 days followed by oral tramadol (0.1 g tid) for 4 days
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib (40 mg bid) for 3 days followed by oral celecoxib (0.2 mg bid) for 4 days
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intravenous parecoxib (40 mg bid) for 3 days
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intravenous tramadol (0.1 g tid) for 3 days
Number of subjects: 112
Study: 21209300

Group type: EXPERIMENTAL
Intervention: EDSS-supported planning group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care planning group
Number of subjects: 80
Study: 19144094

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71
Study: 17702193

Group type: EXPERIMENTAL
Intervention: Test formulation of nifuratel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of nifuratel
Number of subjects: 24
Study: 15025738

Group type: EXPERIMENTAL
Intervention: Levosimendan at 0.05 micro g kg(‐1) min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levosimendan at 0.1 micro g kg(‐1) min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levosimendan (both doses)
Number of subjects: 24
Study: 11490051

Group type: EXPERIMENTAL
Intervention: Workshop and feedback reports only
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Workshop and feedback reports with clinical consultation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control
Number of subjects: 113
Study: 9734737

Group type: EXPERIMENTAL
Intervention: Amino acids, glucose, and lipid infusion for 3 hours
Number of subjects: 14
Study: 8291598

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops, six times, one drop every three hours until 90 minutes preoperatively
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops, two additional instillations, one drop every 30 minutes until 30 minutes before aspiration
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin, single 200‐mg dose
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin, 200 mg infusion
Number of subjects: 51
Study: 31008690

Group type: EXPERIMENTAL
Intervention: Parenchymal thickness measurement
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Parenchymal thickness < 11.4 mm
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Volumetric measurements
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Resected volume comparison
Number of subjects: 37

Group type: COMPARATOR
Intervention: Postoperative MTG comparison
Number of subjects: 37
Study: 30783328

Group type: EXPERIMENTAL
Intervention: Heparin topical solution (1000 IU/ml)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Heparin topical gel (200 IU/g)
Number of subjects: 84
Study: 26632520

Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg/wk)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 24910102

Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ketamine (all doses)
Number of subjects: 4
Study: 23076752

Group type: EXPERIMENTAL
Intervention: HRA patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: THA patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HRA and THA patients combined
Number of subjects: 3
Study: 20459399

Group type: EXPERIMENTAL
Intervention: Carvedilol (24 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Metoprolol tartrate (24 weeks)
Number of subjects: 77
Study: 18096843

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study: 16636154

Group type: EXPERIMENTAL
Intervention: Coalition formation and implementation stages
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coalition maintenance stage
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coalition institutionalization stage
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Community mobilization
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Responsiveness to community needs and comprehensive strategies
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Innovative and achievable goals
Number of subjects: 16
Study: 14661491

Group type: EXPERIMENTAL
Intervention: Injection rate of 5 mL/sec
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All study groups with injection rates of 3 ml/sec and 5 mL/sec
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preselected threshold of 50 HU
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with injection rate of 3 ml/sec and 60 sec delay time
Number of subjects: 100
Study: 10720274

Group type: EXPERIMENTAL
Intervention: Left-sided pallidotomy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Right-sided pallidotomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (pallidotomy after 6 months)
Number of subjects: 35
Study: 8857868

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 276

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 276
Study: 1516676

Group type: EXPERIMENTAL
Intervention: Vitamin B12 (methylcobalamin) 3 mg/day for 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12266391

Group type: EXPERIMENTAL
Intervention: DIANE combined low dose treatment (2 mgr Androcur and .05 mgr of EE in 21‐day cycles)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High dose combination (50 mgr Androcur and .05 mgr of EE in 21 day cycles)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous administration of Androcur (25‐150 mgr)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High dose combination
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DIANE
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High dose continuous method
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low dose combined method
Number of subjects: 54
Study: 31884313

Group type: EXPERIMENTAL
Intervention: PSA-DBS
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: VIM-DBS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Preoperative speech without DBS
Number of subjects: 13